This may imply that genes affected by these disease-associated CNAs may have oncogenic roles in ASPS sarcomagenesis, suggesting the potential utility of CDK4/MDM2 inhibitors for the treatment of this disease. Here, MDM2 is linked to alveolar soft part sarcoma.